

Study Number: C13115-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary

Test Compound: 3-(2H-Benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester

CAS Number: 84268-23-5

Date Report Requested: 04/24/2026

Time Report Requested: 11:08:53

Lab: Battelle

Study Number:

C13115-01

Study Sex:

Male

PWG Approval Date:

See web page for date of PWG Approval

Version:

v1.7.6

Stat Version:

2023.02.27S

Study Number: C13115-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary

Test Compound: 3-(2H-Benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester

CAS Number: 84268-23-5

Date Report Requested: 04/24/2026

Time Report Requested: 11:08:53

Lab: Battelle

Male													
Treatment Groups (mg/kg)													
	Phase Day	0			30			100			300		
Hematocrit (%)	SD 14	53.1	±	1.0 (5) **	51.2	±	0.8 (5)	49.2	±	0.6 (5) *	51.6	±	1.4 (4) *
Percent of Control					96.4			92.6			97.1		
Manual Hematocrit (%)	SD 14	51.8	±	1.2 (5) **	50.2	±	0.9 (5)	48.0	±	0.7 (5)	50.8	±	0.8 (4)
Percent of Control					96.9			92.7			98.0		
Hemoglobin (g/dL)	SD 14	16.3	±	0.3 (5)	15.8	±	0.2 (5)	15.3	±	0.1 (5)	16.2	±	0.3 (4)
Percent of Control					96.6			93.6			99.0		
Erythrocytes (10 ⁶ /uL)	SD 14	9.35	±	0.19 (5)	8.67	±	0.13 (5)	8.57	±	0.13 (5) *	9.28	±	0.19 (4)
Percent of Control					92.7			91.7			99.3		
Reticulocytes (10 ³ /uL)	SD 14	197.4	±	21.4 (5)	221.7	±	10.3 (5)	238.2	±	23.0 (5)	167.6	±	5.1 (4)
Percent of Control					112.3			120.7			84.9		
Mean Cell Volume (fL)	SD 14	56.9	±	0.3 (5) **	59.1	±	0.8 (5)	57.4	±	0.9 (5)	55.7	±	0.5 (4)
Percent of Control					104.0			100.9			97.9		
Mean Cell Hemoglobin (pg)	SD 14	17.5	±	0.2 (5)	18.2	±	0.3 (5)	17.8	±	0.2 (5)	17.4	±	0.3 (4)
Percent of Control					104.1			101.9			99.8		
Mean Cell Hemoglobin Concentration (g/dL)	SD 14	30.7	±	0.1 (5) **	30.8	±	0.1 (5)	31.0	±	0.2 (5)	31.3	±	0.5 (4)
Percent of Control					100.3			101.1			101.9		
Platelets (10 ³ /uL)	SD 14	784	±	114 (5) **	932	±	83 (5)	1004	±	73 (5)	1145	±	68 (4) *
Percent of Control					118.9			128.1			146.1		
White Blood Cells (10 ³ /uL)	SD 14	9.23	±	0.99 (5)	10.84	±	0.82 (5)	15.62	±	0.83 (5) **	12.02	±	0.63 (4)
Percent of Control					117.4			169.3			130.2		
Neutrophils (10 ³ /uL)	SD 14	0.89	±	0.20 (5) **	0.88	±	0.08 (5)	1.60	±	0.25 (5) *	1.42	±	0.09 (4) *
Percent of Control					99.5			180.4			159.6		

Study Number: C13115-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary

Test Compound: 3-(2H-Benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester

CAS Number: 84268-23-5

Date Report Requested: 04/24/2026

Time Report Requested: 11:08:53

Lab: Battelle

Male

	Phase Day	Treatment Groups (mg/kg)							
		0		30		100		300	
Lymphocytes (10 ³ /uL)	SD 14	7.90 ±	0.84 (5)	9.46 ±	0.66 (5)	13.24 ±	0.65 (5) **	10.05 ±	0.44 (4)
Percent of Control				119.7		167.6		127.2	
Monocytes (10 ³ /uL)	SD 14	0.27 ±	0.04 (5) *	0.31 ±	0.08 (5)	0.47 ±	0.06 (5)	0.33 ±	0.07 (4)
Percent of Control				112.5		172.8		120.4	
Basophils (10 ³ /uL)	SD 14	0.04 ±	0.01 (5)	0.05 ±	0.01 (5)	0.08 ±	0.00 (5) *	0.05 ±	0.01 (4)
Percent of Control				150.0		211.1		145.8	
Eosinophils (10 ³ /uL)	SD 14	0.07 ±	0.01 (5)	0.05 ±	0.01 (5)	0.09 ±	0.02 (5)	0.09 ±	0.02 (4)
Percent of Control				68.6		134.3		132.1	
Large Unstained Cells (10 ³ /uL)	SD 14	0.07 ±	0.01 (5)	0.08 ±	0.01 (5)	0.13 ±	0.00 (5) *	0.08 ±	0.01 (4)
Percent of Control				127.3		203.0		121.2	

Study Number: C13115-01**Test Type:** TOX**Route:** Oral Gavage**Species/Strain:** Rat/Harlan Sprague Dawley**PA43: Hematology Summary****Test Compound:** 3-(2H-Benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester**CAS Number:** 84268-23-5**Date Report Requested:** 04/24/2026**Time Report Requested:** 11:08:53**Lab:** Battelle**Male**

	Phase Day	Treatment Groups		
		1000		
Hematocrit (%)	SD 14	41.8 ± 2.7 (4) **		
Percent of Control		78.6		
Manual Hematocrit (%)	SD 14	42.2 ± 2.6 (5) **		
Percent of Control		81.5		
Hemoglobin (g/dL)	SD 14	14.3 ± 1.0 (4)		
Percent of Control		87.8		
Erythrocytes (10 ⁶ /uL)	SD 14	8.17 ± 0.58 (4)		
Percent of Control		87.4		
Reticulocytes (10 ³ /uL)	SD 14	303.3 ± 41.0 (4)		
Percent of Control		153.6		
Mean Cell Volume (fL)	SD 14	51.2 ± 0.6 (4) *		
Percent of Control		90.0		
Mean Cell Hemoglobin (pg)	SD 14	17.6 ± 0.3 (4)		
Percent of Control		100.5		
Mean Cell Hemoglobin Concentration (g/dL)	SD 14	34.3 ± 0.3 (4) **		
Percent of Control		111.6		
Platelets (10 ³ /uL)	SD 14	1087 ± 209 (4) *		
Percent of Control		138.7		
White Blood Cells (10 ³ /uL)	SD 14	10.89 ± 1.97 (4)		
Percent of Control		117.9		
Neutrophils (10 ³ /uL)	SD 14	3.60 ± 0.70 (4) **		
Percent of Control		404.8		

Male

	Phase Day	Treatment Groups	
		1000	
Lymphocytes (10 ³ /uL)	SD 14	6.39 ±	1.88 (4)
Percent of Control		80.9	
Monocytes (10 ³ /uL)	SD 14	0.74 ±	0.24 (4)
Percent of Control		271.1	
Basophils (10 ³ /uL)	SD 14	0.04 ±	0.02 (4)
Percent of Control		104.2	
Eosinophils (10 ³ /uL)	SD 14	0.07 ±	0.02 (4)
Percent of Control		100.0	
Large Unstained Cells (10 ³ /uL)	SD 14	0.06 ±	0.02 (4)
Percent of Control		94.7	

Study Number: C13115-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary

Test Compound: 3-(2H-Benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester

CAS Number: 84268-23-5

Date Report Requested: 04/24/2026

Time Report Requested: 11:08:53

Lab: Battelle

LEGEND

Values given as mean $\pm$ SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100.

SD = Study Day

Statistical analysis was performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test.

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group.

* Statistically significant at $p \leq 0.05$

** Statistically significant at $p \leq 0.01$

SEM = Standard Error of the Mean

Hematology data not reported was removed as an outlier, or was due to pre-analytical or analytical conditions or errors including but not limited to: short sample, quantity not sufficient, or clotted sample.

**** END OF REPORT ****